Autoimmune Market Forecast to 2014 : Market Research Report

Autoimmune Market Forecast to 2014

Published by: Cutting Edge Information

Published: Jun. 1, 2009 - 293 Pages

Product Breakdown: • 43 Profiled Drugs; • 23 Biologics; • 20 Small Molecules; • 6 Indications
Brand Profile Components: • Product history; • Competitive and strategic positioning; • Market growth opportunities; • Sales projection charts; • Materiality charts; • Approval histories; • Market exclusivity and patent information (for approved drugs); • Clinical trial data tables
Company Profile Components: • Autoimmune market ranking; • Strengths analysis; • Growth areas analysis; • Key products breakdown
Chapter 1: Indications: • Psoriasis and Psoriatic Arthritis; • Rheumatoid arthritis; • Systemic Lupus Erythematosus and Lupus Nephritis; • Ulcerative colitis; • Crohn’s disease; • Multiple sclerosis
Chapter 2: Biologics: • B-cell inhibitors; • Rituxan; • Arzerra; • Lymphostat-B; • Ocrelizumab; • Atacicept; • TRU-015; • Interleukin inhibitors; • Actemra; • Stelara; • ACZ885; • Other biologics; • Campath; • Orencia; • Tysabri; • Prochymal; • Denosumab; • Dirucotide; • TNF inhibitors; • Cimzia; • Enbrel; • Humira; • Remicade; • Simponi; • Interferon betas; • Avonex; • Betaseron; • Rebif
Chapter 3: Small Molecules: • Immunomodulators; • Copaxone; • BG-12; • Fingolimod; • Laquinimod; • NSAIDs; • Arthrotec; • Celebrex; • 5-ASAs; • Asacol; • Lialda; • Pentasa; • Corticosteroids; • Entocort EC; • Taclonex; • Antimetabolites; • CellCept; • Cladibrine; • Teriflunomide; • JAK inhibitors; • CP-690,550; • INCB18424; • Other profiled small molecules; • Fampridine SR; • Apremilast; • AZD9056; • Firategrast
Chapter 4: Autoimmune Drug Manufacturer Profiles
The report details nine companies projected to have the top autoimmune franchises in their portfolios. What are their strategies for success? What products are they relying on? What challenges will they confront in the next few years?: • Abbott; • Roche; • Centocor (Johnson & Johnson); • Biogen Idec; • Amgen; • Pfizer; • Schering-Plough (Merck); • Merck KGaA; • Teva

Abstract

Drive blockbuster revenue with autoimmune breakthroughs The autoimmune market is proving that the era of the blockbuster is not dead.

Of 14 brands already at or expected to reach blockbuster status, half generate at least $3 billion annually. Nine mid-level products will generate $400 million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level success is an expectation as much as a goal.

Whether you're exploring your options or need to increase your presence in the market, autoimmune compounds provide lucrative opportunities -- don't miss out!

From sales projections to clinical trial data to analysts' insights, Autoimmune Market Forecast to 2014 tells you everything you need to know. Unlike other market forecast reports out there, ours covers all of the major indications - rheumatoid arthritis, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis and lupus - profiling 40+ drugs and nine leading autoimmune product manufacturers.

Delve into the data to:

Learn how brands and drug classes have fared: where they've succeeded - and failed
Show solid, objective evidence for your decision-making
Keep track of the competition
Get the latest on clinical trials
Uncover potential business development opportunities

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Autoimmune Market Forecast to 2014

Table of Contents

Abstract